摘要
探究重组人促红素(rHuEPO)注射液单用及联合罗沙司他对维持性腹膜透析(MPD)患者肾性贫血的治疗效果及对铁代谢、炎症指标的影响。研究对象选自医院2023年1月—2025年1月收治的MPD患者,采用随机数表法分组,患者被分为观察组和对照组,每组各55例。对照组予以单用rHuEPO注射液治疗,观察组予以rHuEPO注射液联合罗沙司他治疗。比较治疗12周后两组患者的临床疗效;比较治疗前及治疗12周后两组患者的贫血指标[红细胞计数(RBC)、红细胞压积(Hct)、血红蛋白(Hb)]、铁代谢指标[总铁结合力(TIBC)、转铁蛋白(TRF)、血清铁(Fe)、血清铁蛋白(SF)]、脂代谢指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)]、炎症指标[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)];比较治疗12周内两组患者的用药安全性。治疗12周后,观察组总有效率显著高于对照组(P<0.05);治疗12周后,两组患者贫血指标(RBC、Hct、Hb)、铁代谢(TIBC、TRF、Fe、SF)水平均较治疗前显著升高,且观察组高于对照组(P<0.05);对照组TG水平无显著变化(P>0.05),观察组较治疗前显著降低,且低于对照组(P<0.05),两组患者TC及LDL-C水平均显著降低,且观察组低于对照组(P<0.05);两组患者炎症指标(CRP、TNF-α、IL-6)水平均显著降低,且观察组显著低于对照组(P<0.05);治疗12周内,两组患者不良反应无显著差异(P>0.05)。对于伴有肾性贫血的MPD患者,经rHuEPO注射液与罗沙司他联合治疗后可有效缓解贫血,改善炎症因子水平及脂代谢水平,具有较高的临床有效性及安全性。
This study aimed to explore the therapeutic effect of recombinant human erythropoietin(rHuEPO)injection alone and combined with roxadustat on renal anemia in patients with maintenance peritoneal dialysis(MPD)and its influence on iron metabolism and inflammatory indexes.The study subjects were MPD patients admitted to the hospital from January 2023 to January 2025,and were divided into the observation group and the control group by random number table method,with 55 cases in each group.The control group was treated with rHuEPO injection alone,while the observation group received rHuEPO injection combined with roxadustat.The clinical efficacy after 12 weeks of treatment,anemia indexes[red blood cell count(RBC),hematocrit(Hct),hemoglobin(Hb)],iron metabolism indexes[total iron binding capacity(TIBC),transferrin(TRF),serum iron(Fe),serum ferritin(SF)],lipid metabolism indexes[triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)]and inflammatory indexes[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]before treatment and after 12 weeks of treatment and drug safety within 12 weeks of treatment were compared between the two groups.After 12 weeks of treatment,the overall response rate in the observation group was significantly higher than that in the control group(P<0.05).After 12 weeks of treatment,anemia indexes(RBC,Hct,Hb)and iron metabolism indexes(TIBC,TRF,Fe,SF)in both groups showed significant increases compared to pre-treatment levels,with observation group exhibiting higher levels than control group(P<0.05).TG level showed no significant change in control group(P>0.05)while observation group exhibited a significant decrease compared to before treatment and remained lower than that in control group(P<0.O5).Both groups demonstrated significant reductions in TC and LDL-C levels,with observation group showing lower levels compared to control group(P<0.05).Inflammatory indexes(CRP,TNF-α,IL-6)were decreased significantly in both groups,with observation group showing significantly lower levels(P<0.05).No significant differences in adverse reactions were observed between the two groups within 12 weeks of treatment(P>0.05).For MPD patients with renal anemia,the combination of rHuEPO injection and roxadustat can effectively alleviate anemia,and improve the levels of inflammatory factors and lipid metabolism,with high clinical effectiveness and safety.
作者
邵艺
田恬
邢晋
郭智慧
刘烨
SHAO Yi;TIAN Tian;XING Jin;GUO Zhihui;LIU Ye(Second Department of Nephrology,Cangzhou Central Hospital,Cangzhou O61000,China)
出处
《药物生物技术》
2025年第6期799-803,共5页
Pharmaceutical Biotechnology
基金
河北省2025年度医学科学研究课题计划(No.20250263)。
关键词
维持性腹膜透析
肾性贫血
重组人促红素注射液
罗沙司他
临床疗效
铁代谢
炎症因子
Maintenance peritoneal dialysis
Renal anemia
Recombinant human erythropoietin injection
Roxadustat
Clinical efficacy
Iron metabolism
Inflammatory factors
